← Back to grants
Grant✓ Small businesses may apply

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

National Institutes of Health

Award ceiling

$300,000

Program funding

$300,000

Opportunity #
RFA-DA-26-034
Agency
National Institutes of Health
ALN (CFDA)
93.839, 93.837, 93.840, 93.855, 93.233, 93.279, 93.838
Status
posted
Posted
Nov 20, 2024
Closes
Nov 18, 2027
Funding instrument
Grant
Category
Education, Health
Cost sharing required
No

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Synopsis

This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.

Contact

National Institutes of Health · grantsinfo@nih.gov

View full notice on Grants.gov ↗